Johnson & Johnson Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Johnson & Johnson kazanç ve gelirin sırasıyla yıllık 10.3% ve 3.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 12.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 32.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

10.3%

Kazanç büyüme oranı

12.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	23.6%
Gelir büyüme oranı	3.4%
Gelecekteki özkaynak getirisi	32.7%
Analist kapsamı	Good
Son güncelleme	06 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NYSE:JNJ - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	94,747	22,286	22,201	26,999	18
12/31/2025	91,311	20,759	22,449	26,302	20
12/31/2024	88,781	17,494	17,573	22,586	19
9/29/2024	87,696	14,767	19,025	25,146	N/A
6/30/2024	86,576	16,382	19,833	24,642	N/A
3/31/2024	85,648	17,072	18,234	23,191	N/A
12/31/2023	85,159	13,326	17,778	22,791	N/A
10/1/2023	83,703	12,421	15,737	20,278	N/A
7/2/2023	82,348	12,422	14,547	19,073	N/A
4/2/2023	77,458	10,730	16,207	20,472	N/A
1/1/2023	79,990	16,370	17,185	21,194	N/A
10/2/2022	84,855	17,879	17,739	21,576	N/A
7/3/2022	88,197	17,236	19,950	23,582	N/A
4/3/2022	94,880	19,830	19,733	23,315	N/A
1/2/2022	78,740	17,801	19,758	23,410	N/A
10/3/2021	91,446	17,880	22,461	26,021	N/A
7/4/2021	89,190	17,767	22,564	26,114	N/A
4/4/2021	84,214	15,115	20,853	24,252	N/A
1/3/2021	82,584	14,714	20,189	23,536	N/A
9/27/2020	80,856	16,986	18,307	21,591	N/A
6/28/2020	80,503	15,185	17,443	20,735	N/A
3/29/2020	82,729	17,166	19,764	23,231	N/A
12/29/2019	82,059	15,119	19,918	23,416	N/A
9/29/2019	81,706	14,151	19,706	23,262	N/A
6/30/2019	81,325	16,332	18,377	22,007	N/A
3/31/2019	81,593	14,679	18,470	22,138	N/A
12/30/2018	81,581	15,297	18,531	22,201	N/A
9/30/2018	81,382	1,542	18,470	22,062	N/A
7/1/2018	80,684	1,372	N/A	22,056	N/A
4/1/2018	78,693	1,245	N/A	21,749	N/A
12/31/2017	76,450	1,300	N/A	21,056	N/A
10/1/2017	74,361	15,827	N/A	21,604	N/A
7/2/2017	72,531	16,335	N/A	20,699	N/A
4/2/2017	72,174	16,505	N/A	19,491	N/A
1/1/2017	71,890	16,540	N/A	18,767	N/A
10/2/2016	71,595	15,941	N/A	17,199	N/A
7/3/2016	70,877	15,027	N/A	17,978	N/A
4/3/2016	70,182	15,546	N/A	18,886	N/A
1/3/2016	70,074	15,409	N/A	19,569	N/A
9/27/2015	70,517	14,715	N/A	18,849	N/A
6/28/2015	71,882	16,106	N/A	17,363	N/A
3/29/2015	73,590	15,916	N/A	17,420	N/A
12/28/2014	74,331	16,323	N/A	18,710	N/A
9/28/2014	74,232	17,321	N/A	18,245	N/A
6/29/2014	73,340	15,554	N/A	19,538	N/A
3/30/2014	71,722	15,061	N/A	19,060	N/A
12/29/2013	71,312	13,831	N/A	17,414	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: JNJ 'nin tahmini kazanç büyümesi (yıllık 10.3% ) tasarruf oranının ( 2.6% ) üzerindedir.

Kazançlar ve Piyasa: JNJ şirketinin kazançlarının (yıllık 10.3% ) US pazarından (yıllık 15.4% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: JNJ şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: JNJ şirketinin gelirinin (yıllık 3.4% ) US pazarından (yıllık 8.9% ) daha yavaş büyümesi öngörülüyor.

Yüksek Büyüme Geliri: JNJ şirketinin gelirinin (yıllık 3.4% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: JNJ 'in Özsermaye Getirisi'nin 3 yıl içinde yüksek olması tahmin ediliyor ( 32.7 %)

Johnson & Johnson Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Johnson & Johnson Submits Applications in the U.S. and EU Seek Approval of DARZALEX FASPRO® as Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces Results from Phase 3 GRAVITI Study of Tremfya

Johnson & Johnson Highlights Innovative Neuropsychiatry Portfolio and Pipeline at Psych Congress

Johnson & Johnson Announces New Spectrem Study Findings Reveal Tremfya (Guselkumab) Effectively Clears Overlooked and Undertreated Plaque Psoriasis

Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth

Third quarter dividend of US$1.24 announced

Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson Announces Positive Results from the Phase 2/3 Vibrance-MG Study of Nipocalimab

Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth

Johnson & Johnson Announces Tremfya Data in Both Crohn's Disease and Ulcerative Colitis

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson: A Sell-Rated Dividend King

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson: Don't Bet Against Double Compounding

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin